TARA NASDAQ
Credit Risk of going bust: lower than 58% of companies Debt: 1.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.7%), Protara Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.7M against a stock market value of $138.9M.
Distance to default 5.97 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.4M (short-term plus half of long-term), stock volatility 74.4%; Altman Z'' 7.46. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New York City, NY 10010
US
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Shefferman Jesse | G-Gift | 14,000 | — | 2026-06-30 |
| Shefferman Jesse | G-Gift | 7,000 | — | 2026-06-30 |
| Shefferman Jesse | G-Gift | 4,000 | — | 2026-06-30 |
| Shefferman Jesse | G-Gift | 5,000 | — | 2026-06-30 |
| Shefferman Jesse | M-Exempt | 215,687 | $1.91 | 2026-06-29 |